Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Selecta Biosciences Inc (SELB): OrbiMed Advisors Reports New Stake

Page 1 of 13

Samuel Isaly’s Orbimed Advisors recently filed a Form 13D with the Securities and Exchange Commission, in which it reported a new stake in Selecta Biosciences Inc (NASDAQ:SELB). The position amasses 1.84 million shares, which account for 10.03% of the outstanding stock of the company. The filing also revealed that this acquisition of shares is solely for investment purposes and that the fund will continue to further examine its investment by monitoring the company’s business moves.

Selecta Biosciences is a clinical-stage biopharmaceutical company that works on discovering therapeutics that could help patients who suffer from a variety of serious and rare conditions. The company recently started trading on the Nasdaq, on June 23, and its shares have remained largely unchanged since then, save for a short downward blip on June 24. The company has a market cap of $250 million.

Samuel Isaly - Orbimed Advisors

You can access the original SEC filing by clicking here.

Follow Selecta Biosciences Inc
Trade (SELB) Now!

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
OrbiMed Advisors 0 1,842,797 0 1,842,797 1,842,797 10.3%
OrbiMed Capital GP III 0 1,825,415 0 1,825,415 1,825,415 10.2%
Samuel D. Isaly 0 1,842,797 0 1,842,797 1,842,797 10.3%

Samuel Isaly
Samuel Isaly
OrbiMed Advisors

Page 1 of 13 – SEC Filing



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934

SELECTA BIOSCIENCES, INC.


(Name of Issuer)

COMMON STOCK


(Title of Class of Securities)

816212104


(CUSIP Number)
OrbiMed Advisors LLC
OrbiMed Capital GP III LLC
Samuel D. Isaly
601 Lexington Avenue, 54th Floor
New York, NY 10022

Telephone:  (212) 739-6400


(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)

June 27, 2016


(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  o.
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7(b) for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


Follow Selecta Biosciences Inc
Trade (SELB) Now!
Page 1 of 13

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!